Cipla announces Africa expansion strategy

The symbolic Aids awareness ribbon for Cipla recently announced that negotiations to establish manufacturing facilities in Morocco and later in Algeria are in advanced stages of discussion. The pharmaceutical manufacturer aims to establish these facilities through joint ventures, thereby increasing its antiretroviral (ARV) manufacturing capacity in Africa.

This is according to Paul Miller, CEO of Cipla SA, who says that currently one in three HIV/Aids patients in Africa uses a Cipla product. ‘These ARVs are produced by Cipla Medpro Manufacturing (CMM), based in KwaZulu-Natal and Cipla Quality Chemical Industries (CiplaQCLI) in Uganda. CiplaQCLI currently manufactures ARVs for the treatment of approximately 250 000 patients. We hope to significantly increase our manufacturing capacity on the continent through the new manufacturing facilities in Morocco and Algeria.’

Cipla has also commissioned a dedicated ARV manufacturing facility in India in order to double its manufacturing capacity. ‘This unit has been made ready in a record period of nine months. It was commissioned to meet the increased demand for ARVs in order to treat 90 percent of the HIV population – as per the World Health Organization’s ambitious 90-90-90 programme,’ Miller adds.

Providing hope and saving lives

The previous International Aids Conference, which took place in Durban, KZN, in 2000, marked a time when close to 8 000 patients were dying daily from Aids-related infections. This, according to Miller, was mainly due to insufficient access to affordable medication. ‘Since then, Cipla – under the guidance of Chairman, Dr Yusuf Hamied – has played a significant part in saving the lives of approximately 10 million Africans. This is thanks to the development of the unique fixed-dose-combination ARVs available for a dollar a day,’ he explains.  

Today Cipla supplies ARVs to over 100 countries and reaches approximately 20 million patients globally – most of which are based in Africa.

Private and public sector collaboration

Pointing to the decision of the South African Department of Health to distribute ARVs to all HIV patients regardless of their CD4 count from September this year, Miller says a team effort between government and pharmaceutical manufacturers will play key role to play in seeing this objective is reached. This is especially relevant to those pharmaceutical manufacturers servicing the 2015/17 national ARV tender.

Substantial capacity developments

In an effort to provide for the increased ARV demand, Cipla SA has recently invested R500 million in upgrading its local manufacturing facility, CMM. This is to ensure it is Pharmaceutical Inspection Co-operation Scheme (PIC/S) compliant. ‘These upgrades, together with the medication provided by our India based partner, Cipla Limited, will ensure that we are able to fulfil an increased ARV quota,’ comments Miller.

‘We are currently developing unique fixed-dose combinations and formulations. We will also continue to promote new molecules and innovative fixed-dose combinations as well as licencing agreements to ensure fair returns for investors and affordable prices for patients. Cipla is further working on nanoparticles, which will substantially bring down the cost of anti-Aids drugs.’

In closing, Miller says: ‘We are honoured to host key stakeholders and activists at the Durban2Durban forum where we will discuss the huge strides that was taken over the last 16 years and the way forward.’



Latest


18 Jun 2021
BaoCare enters the New Product Competition

Inspired by the abundant riches that come from the baobab, BaoCare is a range of 100% pure and natural skin…

BaoCare enters the New Product Competition

Inspired by the abundant riches that come from the baobab, BaoCare is a range of 100% pure and natural skin care serums formulated with baobab oil as its foundational hero ingredient. BaoCare has entered this range in the 2020/2021 P&C Review / Symrise New Product Competition. Each BaoCare product combines…

17 Jun 2021
Signature Collection line of EDTs re-launched by Playboy

An Amka brand, Playboy has re-launched its Signature Collection with fresh new packaging. The well-known South African brand has also…

Signature Collection line of EDTs re-launched by Playboy

An Amka brand, Playboy has re-launched its Signature Collection with fresh new packaging. The well-known South African brand has also unveiled an Eau De Toilette (EDT) collection to complement the range.  “The Playboy Signature Collection is for the confident man – he is self-assured and is at the stage of…

17 Jun 2021
Seven-day countdown to ending maskne with Miracne

Acne is a skin condition affecting approximately 9.4% of the world’s population and is the eighth most common cutaneous problem.…

Seven-day countdown to ending maskne with Miracne

Acne is a skin condition affecting approximately 9.4% of the world’s population and is the eighth most common cutaneous problem. It is extremely common among teenagers – an estimated 85% of this consumer group suffer from acne. Although it typically fades with age, the skin condition is still prevalent among…

17 Jun 2021
Vantage earns an EcoVadis Gold sustainability rating

Vantage Specialty Chemicals is committed to sustainability. In December 2020, the company earned its first-ever EcoVadis Gold rating for its…

Vantage earns an EcoVadis Gold sustainability rating

Vantage Specialty Chemicals is committed to sustainability. In December 2020, the company earned its first-ever EcoVadis Gold rating for its 2020 Corporate Social Responsibility (CSR) performance. The Gold rating acknowledges the commitment and continual sustainability achievements of Vantage and elevates the company into the top 5% of evaluated chemical companies…


Top stories


30 Nov 2017
Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form…

Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form of diabetes, known as “type 3” diabetes and Alzheimer’s disease.

25 Jun 2020
How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a…

How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a changing environment, whether it be internal or external. Qualities of agile businesses include being adaptive, flexible and creative in your response to change without losing momentum (remaining productive) or vision.…

01 May 2020
Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex,…

Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex, which continuously invests in technological advancements to meet requirements in diverse industries – has increased production capacity of materials so desperately needed during the global COVID-19 pandemic,” explains Rosa Naidoo,…

23 Apr 2020
Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love.…

Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love. Santam, Fairlady and, for the first time this year, Truelove Magazine, have partnered up in the search to find the best female entrepreneurs in the country. Best women entrepreneurs If…


Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za